Joshi Kalpesh K, Nerurkar Rajan P
Department of Pharmacology, TNMC & BYL Nair Charitable hospital, Mumbai.
Indian J Physiol Pharmacol. 2012 Oct-Dec;56(4):367-74.
Many drugs, including serratiopeptidases, are marketed without proven efficacy in clinical trials. It is protein in nature and claimed to be effective orally.
24 albino wistar rats, 6 each in following groups were assigned--(1) Control group (distilled water, orally) (2) Diclofenac (6.75 mg/kg, IP) (3) serratiopeptidase (5.4 mg/kg, orally) (4) Combination of serratiopeptidase (5.4 mg/kg, orally) and diclofenac (2.25 mg/kg, IP). Inflammatory agent, carrageenan (0.1 ml of 1% w/v) was injected subcutaneously in the ether anesthetized rat hind paw, half an hour after the administration of drug. Rat paw volume up to lateral malleolar process was recorded with plethysmometer at various time periods.
Percentage formation and inhibition of oedema in serratiopeptidase or combination groups were not significantly different than control group. Both were significantly less for diclofenac group.
Serratiopeptidase was not effective in this animal model of oedema/inflammation.
包括沙雷氏肽酶在内的许多药物在临床试验中未经证实疗效就已上市。它本质上是一种蛋白质,据称口服有效。
将24只白化Wistar大鼠分为以下几组,每组6只——(1)对照组(口服蒸馏水)(2)双氯芬酸(6.75毫克/千克,腹腔注射)(3)沙雷氏肽酶(5.4毫克/千克,口服)(4)沙雷氏肽酶(5.4毫克/千克,口服)与双氯芬酸(2.25毫克/千克,腹腔注射)联合用药组。在给药半小时后,将炎症介质角叉菜胶(0.1毫升1% w/v)皮下注射到乙醚麻醉的大鼠后爪中。在不同时间段用体积描记器记录大鼠踝关节外侧突起处的爪体积。
沙雷氏肽酶组或联合用药组水肿的形成和抑制百分比与对照组无显著差异。双氯芬酸组两者均显著低于对照组。
在这种水肿/炎症动物模型中,沙雷氏肽酶无效。